Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention

Archives of Internal Medicine

Volumn 158, Issue 6, 1998, Pages 655-662

  Grover, Steven A ^a,b   Paquet, Steve ^a   Levinton, Carey ^a   Coupal, Louis ^a   Zowall, Hanna ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; FATALITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFE EXPECTANCY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; STROKE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; FEMALE; FORECASTING; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE EXPECTANCY; MALE; MIDDLE AGED; PRIMARY PREVENTION; RECURRENCE; RISK FACTORS;

EID: 0032559842     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.6.655     Document Type: Article

References (38)

1. Pedersen TR, Kjekshus J, Berg K, et al, for the Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1009.
3. Grouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids, and artherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
4. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipolniacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-28.
5. Furberg CD, Byington RP, Crouse JR, et al. Pravastatin, lipids and major coronary events. Am J Cardiol. 1994;73:1133-1134.
6. Welin LZ, Svärdsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med. 1987;317:521-526.
7. Hebert PR, Gaziano M, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
8. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1993;119:136-145.
9. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD, for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904-910.
10. Andersen KM, Odell PM, Wilson PWF, Kannel WB Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-298.
11. Hamilton VH, Racicot FE, Zowall H, Coupai L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA. 1995;273:1032-1038.
12. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
13. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991;67: 789-796.
14. Kinosian BP, Eisenberg JM. Cutting into cholesterol, cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;259:2249-2254.
15. Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA. 1987;258: 2381-2387
16. Central Patient Registry and Coordinating Centre for the Lipid Research Clinics. Reference Manual for the Lipid Research Clinics Prevalence Study. Vols 1 and 2. Chapel Hill: University of North Carolina; 1974.
17. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Prevalence Study. Circulation. 1979;60:427-439.
18. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1980;61:302-315.
19. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Vol 1. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; 1974. US Dept of Health, Education and Welfare publication NIH 75-628.
20. Grover SA, Coupai L, Hu X-P. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA. 1995;274: 801-806.
21. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
22. Kannel WB, Wolf PA, Garrison RJ. Survival following initial cardiovascular events: 30-year follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; 1988:§35. Publication NIH 88-2969.
23. Manninen V, Elo O, Frick H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
24. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
25. Buchwald H, Varco RL, Matts JP, et al, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323:946-955.
26. SHEP Cooperative Research Group. Prevention of stroke antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265: 255-264.
27. Wikstrand J, Warnold I, Olsson G, Tuomilheto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. JAMA. 1988; 259:1976-1982.
28. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a priori hypothesis of the trial. JAMA. 1990;263:1795-1801.
29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
30. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 1996;27:964-1057.
31. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.
32. Abbott RD, McGee D, Kannel WB, Wolf PA, Garrison RJ. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: US Dept of Health, Education and Welfare; 1987:§37. Publication NIH 87-2284.
33. Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupai L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA. 1992;267:816-822.
34. Taylor WC, Pass TM, Shepard DS, Komaroff AL. Cholesterol reduction and life expectancy: a model incorporating multiple risk factors. Ann Intern Med. 1987; 106:605-614.
35. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 1991;83:1194-1201.
36. Crouse JR III, Byington RP, Furberg CD. Reductase inhibitor monotherapy prevents stroke. Circulation. 1996;94(suppl):I-540.
37. Garber AM, Littenberg B, Sox HC, Wagner JL, Gluck M. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med. 1991;151:1089-1095.
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 1993;269:3015.